530019 Stock Overview
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide.
Jubilant Pharmova Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹412.50|
|52 Week High||₹925.00|
|52 Week Low||₹384.85|
|1 Month Change||-10.59%|
|3 Month Change||-6.07%|
|1 Year Change||-50.54%|
|3 Year Change||-20.65%|
|5 Year Change||-42.95%|
|Change since IPO||1,746.16%|
Recent News & Updates
|530019||IN Pharmaceuticals||IN Market|
Return vs Industry: 530019 underperformed the Indian Pharmaceuticals industry which returned -10.4% over the past year.
Return vs Market: 530019 underperformed the Indian Market which returned 10.6% over the past year.
|530019 Average Weekly Movement||6.6%|
|Pharmaceuticals Industry Average Movement||7.0%|
|Market Average Movement||7.3%|
|10% most volatile stocks in IN Market||10.0%|
|10% least volatile stocks in IN Market||4.8%|
Stable Share Price: 530019 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 530019's weekly volatility (7%) has been stable over the past year.
About the Company
|1978||6,000||Hari Shanker Bhartia||https://www.jubilantpharmova.com|
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States.
Jubilant Pharmova Fundamentals Summary
|530019 fundamental statistics|
Is 530019 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|530019 income statement (TTM)|
|Cost of Revenue||₹14.62b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 20, 2022
|Earnings per share (EPS)||33.12|
|Net Profit Margin||8.53%|
How did 530019 perform over the long term?See historical performance and comparison
1.2%Current Dividend Yield
Is Jubilant Pharmova undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 530019 (₹412.5) is trading below our estimate of fair value (₹505.81)
Significantly Below Fair Value: 530019 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 530019 is good value based on its PE Ratio (12.5x) compared to the Indian Pharmaceuticals industry average (21.4x).
PE vs Market: 530019 is good value based on its PE Ratio (12.5x) compared to the Indian market (20.6x).
Price to Earnings Growth Ratio
PEG Ratio: 530019 is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: 530019 is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.6x).
How is Jubilant Pharmova forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 530019's forecast earnings growth (20.4% per year) is above the savings rate (6.7%).
Earnings vs Market: 530019's earnings (20.4% per year) are forecast to grow faster than the Indian market (18.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 530019's revenue (7.8% per year) is forecast to grow slower than the Indian market (11.9% per year).
High Growth Revenue: 530019's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 530019's Return on Equity is forecast to be low in 3 years time (10.9%).
How has Jubilant Pharmova performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 530019 has high quality earnings.
Growing Profit Margin: 530019's current net profit margins (8.5%) are lower than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: 530019's earnings have grown by 3.4% per year over the past 5 years.
Accelerating Growth: 530019's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 530019 had negative earnings growth (-36.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).
Return on Equity
High ROE: 530019's Return on Equity (10.3%) is considered low.
How is Jubilant Pharmova's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 530019's short term assets (₹32.6B) exceed its short term liabilities (₹11.6B).
Long Term Liabilities: 530019's short term assets (₹32.6B) exceed its long term liabilities (₹32.1B).
Debt to Equity History and Analysis
Debt Level: 530019's net debt to equity ratio (40.9%) is considered high.
Reducing Debt: 530019's debt to equity ratio has reduced from 112.3% to 57.8% over the past 5 years.
Debt Coverage: 530019's debt is well covered by operating cash flow (54.3%).
Interest Coverage: 530019's interest payments on its debt are well covered by EBIT (7.8x coverage).
What is Jubilant Pharmova current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 530019's dividend (1.21%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).
High Dividend: 530019's dividend (1.21%) is low compared to the top 25% of dividend payers in the Indian market (1.58%).
Stability and Growth of Payments
Stable Dividend: 530019's dividends per share have been stable in the past 10 years.
Growing Dividend: 530019's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (15.1%), 530019's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (7.8%), 530019's dividend payments are thoroughly covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hari Shanker Bhartia (65 yo)
Mr. Hari Shanker Bhartia, B.E., B.Tech, serves as Non-Executive Director at DP Eurasia N.V. since April 21, 2021. He serves as the Non-Executive Independent Director of Shriram Pistons & Rings Limited sinc...
CEO Compensation Analysis
Compensation vs Market: Hari Shanker's total compensation ($USD1.57M) is above average for companies of similar size in the Indian market ($USD338.05K).
Compensation vs Earnings: Hari Shanker's compensation has been consistent with company performance over the past year.
Experienced Management: 530019's management team is seasoned and experienced (7.9 years average tenure).
Experienced Board: 530019's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jubilant Pharmova Limited's employee growth, exchange listings and data sources
- Name: Jubilant Pharmova Limited
- Ticker: 530019
- Exchange: BSE
- Founded: 1978
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹65.672b
- Shares outstanding: 159.21m
- Website: https://www.jubilantpharmova.com
Number of Employees
- Jubilant Pharmova Limited
- 1A, Sector 16A
- Uttar Pradesh
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.